Oculis is a clinical stage biotechnology company focused on the development of novel and transformative topical treatments (eye drops) for ophthalmic diseases for both back and front of the eye. Oculis’ most advanced product candidate based on the solubilizing nanoparticle (SNP) technology is OC-118. OC-118 is being developed in diabetic macular edema (DME) and in front of the eye indications.
Oculis
